Breast Cancer Research and Treatment

, Volume 66, Issue 1, pp 83–87 | Cite as

Phase II study of weekly gemcitabine in patients with metastatic breast cancer relapsing or failing both an anthracycline and a taxane

  • C.H. Smorenburg
  • M. Bontenbal
  • C. Seynaeve
  • C. van Zuylen
  • G. de Heus
  • J. Verweij
  • R. de Wit

Abstract

A phase II study was performed to investigate the efficacy and tolerability of gemcitabine as third-line chemotherapy for patients with metastatic breast cancer, previously treated with both an anthracycline - and taxane-containing regimen. Twenty-three patients were treated with gemcitabine 1200 mg/m2 in a 30-min infusion on day 1, 8 and 15 of a 28 day cycle. Seventy-four percent of the patients had visceral metastases. No complete or partial responses were observed. Six patients (26%) had stable disease with a median duration of 4.0 months. The median time to progression was 1.9 months and the median survival time was 7.8 months. Neutropenia grade 3 and 4 was observed in four patients (18%). Non-hematological toxicity grade 3 included nausea and vomiting in 14%, skin toxicity in 9% and elevation of transaminases in 23% of the patients. Gemcitabine is ineffective as third-line single agent therapy in patients failing anthracycline and taxane treatment for metastatic breast cancer.

breast cancer chemotherapy gemcitabine third-line treatment 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Greenberg PAC, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14: 2197-2205, 1996Google Scholar
  2. 2.
    Fossati R, Confalonieri C, Torri V, Ghislandi E, Penna A, Pistotti V, Tinazzi A, Liberati A: Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31, 510 women. J Clin Oncol 16: 3439-3460, 1998Google Scholar
  3. 3.
    Miller KD, Sledge GW: The role of chemotherapy for metastatic breast cancer. Haemat Oncol Clin North Am 13: 415-434, 1999Google Scholar
  4. 4.
    Crown J: Evolution in the treatment of advanced breast cancer. Semin Oncol 25: 12-17, (Suppl 12) 1998Google Scholar
  5. 5.
    Perez EA: Current management of metastatic breast cancer. Semin Oncol 26: 1-10, (Suppl 12) 1999Google Scholar
  6. 6.
    Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 17: 485-493, 1999Google Scholar
  7. 7.
    Carmichael J: The role of gemcitabine in the treatment of other tumours. Br J Cancer 78: 21-25, (Suppl 3) 1998Google Scholar
  8. 8.
    Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V: Gemcitabine: metabolism, mechanism of action and self-potentiation. Semin Oncol 22: 3-10, (Suppl 11) 1995Google Scholar
  9. 9.
    Lüftner D, Flath B, Akrivakis C, Grunewald R, Mergenthaler HG, Possinger K: Gemcitabine for palliative treatment in metastatic breast cancer. J Cancer Res Clin Oncol 124: 527-531, 1998Google Scholar
  10. 10.
    McLachlan SA, Pintilie M, Tannock IF: Third line chemotherapy in patients with metastatic breast cancer: an evaluation of quality of life and cost. Breast Cancer Res Treat 54: 213-223, 1999Google Scholar
  11. 11.
    Possinger K: Gemcitabine in advanced breast cancer. Anti-Cancer Drugs 6: 55-59, (Suppl 6) 1995Google Scholar
  12. 12.
    Carmichael J, Possinger K, Phillip P, Beykirch M, Kerr H, Walling J, Harris AL: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995Google Scholar
  13. 13.
    Blackstein M, Vogel CL, Ambinder R, Cowan J, Pearce P, Iglesias J: Phase II study of gemcitabine in patients with metastatic breast cancer. (Abstract) Eur J Cancer 33: 149, (Suppl 8) 1997Google Scholar
  14. 14.
    Possinger K, Kaufmann M, Coleman R, Stuart NSA, Helsing M, Ohnmacht U, Arning M: Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-Cancer Drugs 10: 155-162, 1999Google Scholar
  15. 15.
    Spielmann M, Kalla S, Llombart-Cussac A, Espié M, Namer M, Ferrero JM, Cuvier C, Fumoleau P, Ponzio A, Kayitalire L, Pouillart P: Activity of gemcitabine in metastatic breast cancer patients previously treated with anthracycline-containing regimens. (Abstract) Eur J Cancer 33: 149, (Suppl 8) 1997Google Scholar
  16. 16.
    Akrivakis K, Schmid P, Flath B, Schweigert M, Sezer O, Mergenthaler HG, Possinger K: Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anti-Cancer Drugs 10: 525-531, 1999Google Scholar
  17. 17.
    Schmid P, Akrivakis K, Flath B, Grosse Y, Sezer O, Mergenthaler HG, Possinger K: Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anti-Cancer Drugs 10: 625-631, 1999Google Scholar
  18. 18.
    Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C, Adamkiewicz BB, Long CA: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395-1400, 1997Google Scholar
  19. 19.
    Ibrahim NK, Rahman Z, Valero V, Willey J, Theriault RL, Buzdar AU, Murray JL, Bast R, Hortobagyi GN: Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. Cancer 86: 1251-1257, 1999Google Scholar
  20. 20.
    Udom DI, Vigushin DM, Linardou H, Graham H, Palmieri C, Coombes RC: Two weekly vinorelbine: administration in patients who have received at least two prior chemotherapy regimens for advanced breast cancer. Eur J Cancer 36: 177-182, 2000Google Scholar
  21. 21.
    Mickiewicz E, Alvares AM, Brosio C, Giglio R, Cinat G, Rodger J, Nicolás C: A promising second line treatment with weekly taxol in anthracycline recurrent, advanced breast cancer patients. (Abstract) Proc Am Soc Clin Oncol 18: 135, 1999Google Scholar
  22. 22.
    Waintraub SE, Cantwell S, De Vries J: Phase II study to evaluate the efficacy of weekly paclitaxel in patients with metastatic breast cancer who have failed prior anthracycline +/-taxane therapy. (Abstract) Proc Am Soc Clin Oncol 18: 138, 1999Google Scholar
  23. 23.
    Alvarez AM, Mickiewicz E, Brosio C, Giglio R, Cinat G, Rodger J, Nicolás C: Reinduction of response with weekly taxol in advanced breast cancer. (Abstract) Proc Am Soc Clin Oncol 18: 165, 1999Google Scholar
  24. 24.
    Hortobagyi GN: Recent progress in the clinical development of docetaxel (Taxotere): Semin Oncol 26: 32-36, (Suppl 9) 1999Google Scholar
  25. 25.
    Gennari A, Donati S, Danesi R, Fogli S, Orlandini C, del Tacca M, Conte PF: The gemcitabine/epirubicin/paclitaxel combination in advanced breast cancer. Semin Oncol 27: 14-19, (Suppl 2) 2000Google Scholar
  26. 26.
    Péres-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J, Khayat D, Rivelles N: Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 18: 2545-2552, 2000Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • C.H. Smorenburg
    • 1
  • M. Bontenbal
    • 1
  • C. Seynaeve
    • 1
  • C. van Zuylen
    • 1
  • G. de Heus
    • 1
  • J. Verweij
    • 1
  • R. de Wit
    • 1
  1. 1.Department of Medical OncologyRotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital RotterdamRotterdamThe Netherlands

Personalised recommendations